BR112018072063A2 - compostos de pirimidinona fundida substituída - Google Patents

compostos de pirimidinona fundida substituída

Info

Publication number
BR112018072063A2
BR112018072063A2 BR112018072063A BR112018072063A BR112018072063A2 BR 112018072063 A2 BR112018072063 A2 BR 112018072063A2 BR 112018072063 A BR112018072063 A BR 112018072063A BR 112018072063 A BR112018072063 A BR 112018072063A BR 112018072063 A2 BR112018072063 A2 BR 112018072063A2
Authority
BR
Brazil
Prior art keywords
formula
substituted fused
pyrimidinone compounds
fused pyrimidinone
compound
Prior art date
Application number
BR112018072063A
Other languages
English (en)
Inventor
Dutt Chaitanya
Tuli Davinder
Joshi Deepa
Rai Deepak
Abraham Jaya
Rode Milind
Jamadarkhana Prashant
Chandra Gupta Ramesh
Srivastava Sanjay
Deshpande Shailesh
Mishra Vivek
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR112018072063A2 publication Critical patent/BR112018072063A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

são fornecidos novos derivados de pirimidinona fundida de fórmula i e intermediários sintéticos que são úteis na preparação dos compostos de fórmula (i). é proporcionado ainda um método para a preparação de um composto de fórmula (i) ou de seus intermediários, uma composição farmacêutica compreendendo um composto de fórmula (i) e o uso de um composto de fórmula (i).
BR112018072063A 2016-04-26 2017-04-25 compostos de pirimidinona fundida substituída BR112018072063A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621014526 2016-04-26
PCT/IB2017/052352 WO2017187324A1 (en) 2016-04-26 2017-04-25 Substituted fused pyrimidinone compounds

Publications (1)

Publication Number Publication Date
BR112018072063A2 true BR112018072063A2 (pt) 2019-02-12

Family

ID=58745288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072063A BR112018072063A2 (pt) 2016-04-26 2017-04-25 compostos de pirimidinona fundida substituída

Country Status (16)

Country Link
US (1) US20190127381A1 (pt)
EP (1) EP3448855A1 (pt)
JP (1) JP2019514906A (pt)
KR (1) KR20180135486A (pt)
CN (1) CN109071515A (pt)
AR (1) AR108327A1 (pt)
AU (1) AU2017256175A1 (pt)
BR (1) BR112018072063A2 (pt)
CA (1) CA3021542A1 (pt)
EA (1) EA201892370A1 (pt)
IL (1) IL262363A (pt)
MX (1) MX2018012966A (pt)
PH (1) PH12018502246A1 (pt)
SG (1) SG11201809007YA (pt)
TW (1) TW201806953A (pt)
WO (1) WO2017187324A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN111269231B (zh) * 2018-12-04 2023-06-09 安徽中科拓苒药物科学研究有限公司 一种选择性PI3Kδ抑制剂及其用途
CN116987085A (zh) * 2022-04-26 2023-11-03 安徽中科拓苒药物科学研究有限公司 一种PI3Kδ抑制剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760012B1 (fr) 1997-02-26 2000-08-18 Oreal Compositions pour la teinture des fibres keratiniques contenant des para-aminophenols, procede de teinture, nouveaux para-aminophenols et leur procede de prepraration
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2619209A1 (en) * 2010-09-24 2013-07-31 Gilead Calistoga LLC Atropisomers of pi3k-inhibiting compounds
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS

Also Published As

Publication number Publication date
CN109071515A (zh) 2018-12-21
EA201892370A1 (ru) 2019-03-29
WO2017187324A1 (en) 2017-11-02
US20190127381A1 (en) 2019-05-02
TW201806953A (zh) 2018-03-01
MX2018012966A (es) 2019-01-17
PH12018502246A1 (en) 2019-08-19
EP3448855A1 (en) 2019-03-06
IL262363A (en) 2018-11-29
CA3021542A1 (en) 2017-11-02
AU2017256175A1 (en) 2018-11-15
SG11201809007YA (en) 2018-11-29
KR20180135486A (ko) 2018-12-20
JP2019514906A (ja) 2019-06-06
AR108327A1 (es) 2018-08-08
WO2017187324A9 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
NI202000078A (es) Compuestos heteroaril tetracíclicos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR102015032361A8 (pt) Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ECSP16074478A (es) Compuestos novedosos
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CR20160016A (es) Pirazolpiridinas sustituidas
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
BR112018072063A2 (pt) compostos de pirimidinona fundida substituída
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112017021631A2 (pt) composto, composição farmacêutica, combinação farmacêutica, método de tratamento, uso de um composto e processo para preparação de dito composto
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CL2019001804A1 (es) Activador de nrf2.
CO2018007610A2 (es) Derivados de indano y su uso en terapias
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]